{"id":"lopinavir-ritonavir-lpv-r","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lopinavir/ritonavir works by inhibiting the protease enzyme, which is essential for the maturation of viral particles. This prevents the virus from replicating and reduces the viral load in the body. Ritonavir is a booster that increases the levels of lopinavir in the body, allowing for a lower dose and reducing side effects.","oneSentence":"Lopinavir/ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:26.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and children"},{"name":"Prevention of mother-to-child transmission of HIV"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT04487145","phase":"PHASE4","title":"Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-11-23","conditions":"Drug-Drug Interaction, HIV Infection","enrollment":194},{"nctId":"NCT04466241","phase":"PHASE2, PHASE3","title":"Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-11-27","conditions":"COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":294},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT01854762","phase":"PHASE2, PHASE3","title":"Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection","status":"TERMINATED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2015-06-01","conditions":"HIV, Pregnancy","enrollment":33},{"nctId":"NCT04328285","phase":"PHASE3","title":"Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-04-14","conditions":"COVID-19","enrollment":118},{"nctId":"NCT04499677","phase":"PHASE2","title":"FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-24","conditions":"COVID-19","enrollment":240},{"nctId":"NCT02712801","phase":"PHASE4","title":"Antiretroviral Regime for Viral Eradication in Newborns","status":"COMPLETED","sponsor":"National Center for Women and Children's Health, China CDC","startDate":"2016-04","conditions":"HIV/AIDS and Infections","enrollment":600},{"nctId":"NCT03603977","phase":"","title":"Simplified Treatment of Anti-retrovirus in China (C-STAR)","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2017-11-01","conditions":"HIV/AIDS","enrollment":600},{"nctId":"NCT04354428","phase":"PHASE2, PHASE3","title":"Treatment for COVID-19 in High-Risk Adult Outpatients","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-04-16","conditions":"COVID-19, SARS-CoV-2","enrollment":289},{"nctId":"NCT00145795","phase":"PHASE4","title":"A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-04","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT04321174","phase":"PHASE3","title":"COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-04-17","conditions":"Coronavirus Infections, Post-exposure Prophylaxis","enrollment":123},{"nctId":"NCT00109590","phase":"PHASE2","title":"Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":175},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01172535","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"HIV","enrollment":97},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00004855","phase":"NA","title":"Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT02369965","phase":"PHASE3","title":"Test Albuvirtide in Experienced Patients","status":"COMPLETED","sponsor":"Frontier Biotechnologies Inc.","startDate":"2014-02-19","conditions":"HIV Infections, AIDS","enrollment":418},{"nctId":"NCT01818258","phase":"PHASE4","title":"IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-10-26","conditions":"HIV Positive, Malnourished","enrollment":52},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT04138199","phase":"","title":"A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-11-01","conditions":"HIV-1 Infection","enrollment":239},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT01138202","phase":"PHASE2","title":"Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-11","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00627055","phase":"PHASE4","title":"Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT01159275","phase":"PHASE1, PHASE2","title":"Lopinavir (LPV) Dose Reduction","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2009-07","conditions":"HIV-1 Infections","enrollment":20},{"nctId":"NCT00281606","phase":"PHASE4","title":"A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-02-14","conditions":"HIV Infection","enrollment":65},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02415985","phase":"PHASE2","title":"Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2015-06","conditions":"HIV, Tuberculosis","enrollment":40},{"nctId":"NCT01116817","phase":"PHASE4","title":"Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2010-08","conditions":"HIV","enrollment":35},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT03836833","phase":"PHASE1, PHASE2","title":"Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2019-06-04","conditions":"HIV","enrollment":50},{"nctId":"NCT02581202","phase":"","title":"The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-21","conditions":"HIV-1 Infection","enrollment":216},{"nctId":"NCT00993031","phase":"PHASE3","title":"Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12-15","conditions":"Malaria, HIV Infections","enrollment":389},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00608569","phase":"NA","title":"Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV Infections","enrollment":529},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00531986","phase":"PHASE4","title":"HIV - Monotherapy in Switzerland (MOST-ch)","status":"TERMINATED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2007-01","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02671383","phase":"PHASE3","title":"Evaluation of Low-dose Darunavir in a Switch Study","status":"COMPLETED","sponsor":"Willem Daniel Francois Venter","startDate":"2016-06-30","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT02231281","phase":"PHASE3","title":"Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults","status":"UNKNOWN","sponsor":"Yongtao Sun, MD, PhD","startDate":"2014-08","conditions":"Acute HIV Infection","enrollment":65},{"nctId":"NCT00357552","phase":"NA","title":"Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2008-01","conditions":"HIV Infections","enrollment":123},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT01662336","phase":"","title":"Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":173},{"nctId":"NCT01637558","phase":"PHASE4","title":"Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2012-11","conditions":"Tuberculosis, HIV","enrollment":200},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT02348177","phase":"PHASE4","title":"Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2013-01","conditions":"Acquired Immunodeficiency Syndrome, Tuberculosis","enrollment":96},{"nctId":"NCT00307151","phase":"PHASE2","title":"Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2005-12","conditions":"HIV Infections","enrollment":452},{"nctId":"NCT01146873","phase":"PHASE3","title":"Treatment Options for Protease Inhibitor-exposed Children","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-07","conditions":"HIV/AIDS, HIV Infections","enrollment":300},{"nctId":"NCT00474201","phase":"NA","title":"Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2007-05","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT00719602","phase":"EARLY_PHASE1","title":"Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2009-08","conditions":"HIV Infections, Malaria","enrollment":105},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00409591","phase":"PHASE3","title":"Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand","status":"TERMINATED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2008-07","conditions":"HIV Infections, Pregnancy","enrollment":435},{"nctId":"NCT01296152","phase":"PHASE2","title":"Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-05","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT01227590","phase":"PHASE1","title":"Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-02","conditions":"Drug Interactions, Human Immunodeficiency Virus","enrollment":18},{"nctId":"NCT01139905","phase":"PHASE2","title":"Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":24},{"nctId":"NCT00626301","phase":"PHASE4","title":"Lopinavir/Ritonavir Monotherapy in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-11","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01307124","phase":"PHASE3","title":"Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-03","conditions":"HIV-infected Children","enrollment":199},{"nctId":"NCT00023218","phase":"NA","title":"Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":""},{"nctId":"NCT00700115","phase":"PHASE4","title":"Kaletra-isentress Treatment Evaluation","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-06","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02256826","phase":"PHASE1","title":"Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT00978237","phase":"PHASE4","title":"Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2009-10","conditions":"HIV Infections, Lipoatrophy","enrollment":20},{"nctId":"NCT02219672","phase":"PHASE3","title":"Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2014-07","conditions":"AIDS/HIV PROBLEM","enrollment":18},{"nctId":"NCT00640263","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-12","conditions":"HIV Infections","enrollment":1500},{"nctId":"NCT02097381","phase":"NA","title":"Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2010-04","conditions":"HIV Infection","enrollment":10},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00148759","phase":"PHASE4","title":"Kaletra Sex/Gender Pharmacokinetics (PK) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-06","conditions":"HIV Infections","enrollment":23},{"nctId":"NCT00140751","phase":"PHASE3","title":"Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2005-10","conditions":"HIV Infections","enrollment":186},{"nctId":"NCT00865475","phase":"PHASE4","title":"Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-12","conditions":"HIV Infection, HIV Infections","enrollment":38},{"nctId":"NCT00651066","phase":"PHASE2","title":"Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-06","conditions":"HIV Infections, Tuberculosis","enrollment":47},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":"HIV","enrollment":1771},{"nctId":"NCT01383005","phase":"","title":"Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":97},{"nctId":"NCT01031849","phase":"PHASE4","title":"Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir","status":"TERMINATED","sponsor":"Ines Perez","startDate":"2010-02","conditions":"HIV Infections","enrollment":7},{"nctId":"NCT00865007","phase":"PHASE4","title":"Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-12","conditions":"HIV Infection, Lipodystrophy, HIV Infections","enrollment":88},{"nctId":"NCT01166477","phase":"PHASE4","title":"Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"2010-01","conditions":"HIV Infection","enrollment":228},{"nctId":"NCT01159743","phase":"","title":"A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-07","conditions":"HIV Infection","enrollment":346},{"nctId":"NCT00454337","phase":"PHASE3","title":"Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-05","conditions":"HIV Infections","enrollment":170},{"nctId":"NCT01705873","phase":"","title":"Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen","status":"UNKNOWN","sponsor":"Helios Salud","startDate":"2012-09","conditions":"HIV, Hypercholesterolemia, Dyslipidemia","enrollment":300},{"nctId":"NCT00884793","phase":"NA","title":"Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00711009","phase":"PHASE3","title":"Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infection","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-378","lopinavir/ritonavir","LPV/r","Kaletra","Aluvia"],"phase":"phase_3","status":"active","brandName":"lopinavir/ritonavir (LPV/r)","genericName":"lopinavir/ritonavir (LPV/r)","companyName":"French National Agency for Research on AIDS and Viral Hepatitis","companyId":"french-national-agency-for-research-on-aids-and-viral-hepatitis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lopinavir/ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}